UBS Group
BDTX icon

UBS Group’s Black Diamond Therapeutics BDTX Stock Holding History

UBS Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Sell
265,313
-299,525
-53% -$733K ﹤0.01% 6242
2026
Q1 		$1.2M Buy
564,838
+307,205
+119% +$731K ﹤0.01% 5407
2025
Q4 		$626K Sell
257,633
-370,783
-59% -$1.31M ﹤0.01% 5947
2025
Q3 		$2.38M Buy
628,416
+314,716
+100% +$921K ﹤0.01% 4794
2025
Q2 		$778K Buy
313,700
+185,906
+145% +$358K ﹤0.01% 5656
2025
Q1 		$198K Buy
127,794
+77,901
+156% +$163K ﹤0.01% 6569
2024
Q4 		$107K Buy
49,893
+11,436
+30% +$32.8K ﹤0.01% 6830
2024
Q3 		$167K Buy
38,457
+11,923
+45% +$64.9K ﹤0.01% 6011
2024
Q2 		$124K Buy
26,534
+22,263
+521% +$120K ﹤0.01% 6025
2024
Q1 		$21.7K Buy
4,271
+284
+7% +$1.15K ﹤0.01% 6893
2023
Q4 		$11.2K Buy
3,987
+3,741
+1,521% +$8.78K ﹤0.01% 7404
2023
Q3 		$706 Sell
246
-8,273
-97% -$30.5K ﹤0.01% 8323
2023
Q2 		$43K Buy
+8,519
New +$17.4K ﹤0.01% 6560
2023
Q1 		– Sell
-3,433
Closed -$6.18K – 9607
2022
Q4 		$6.18K Sell
3,433
-1,942
-36% -$3.5K ﹤0.01% 9069
2022
Q3 		$9K Sell
5,375
-12,224
-69% -$37.7K ﹤0.01% 8560
2022
Q2 		$44K Sell
17,599
-3,221
-15% -$7.49K ﹤0.01% 6011
2022
Q1 		$58K Sell
20,820
-8,734
-30% -$31.9K ﹤0.01% 6345
2021
Q4 		$157K Buy
29,554
+12,733
+76% +$89K ﹤0.01% 5900
2021
Q3 		$143K Buy
16,821
+5,454
+48% +$53.9K ﹤0.01% 5571
2021
Q2 		$139K Sell
11,367
-31,822
-74% -$629K ﹤0.01% 5622
2021
Q1 		$1.05M Buy
+43,189
New +$1.16M ﹤0.01% 4198
2020
Q4 		– Sell
-197
Closed -$6K – 8382
2020
Q3 		$6K Sell
197
-4,457
-96% -$136K ﹤0.01% 7204
2020
Q2 		$196K Sell
4,654
-2,577
-36% -$94.8K ﹤0.01% 4807
2020
Q1 		$180K Buy
+7,231
New +$220K ﹤0.01% 4799

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

UBS Group's BDTX Position: Q2 2026 in Review

UBS Group reduced its Black Diamond Therapeutics (BDTX) stake by 53% in Q2 2026, selling an estimated $733K and leaving 265,313 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #6242.

UBS Group first reported a position in BDTX in Q1 2020 and has held it in 24 quarters since. The position peaked at $2.38M in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • UBS Group held 265,313 shares of Black Diamond Therapeutics worth $491K as of Q2 2026.
  • UBS Group sold 299,525 Black Diamond Therapeutics shares in Q2 2026, an estimated $733K.
  • Black Diamond Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6242 holding.
  • UBS Group first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • UBS Group's Black Diamond Therapeutics position peaked at $2.38M in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.